Effects of dapagliflozin in treatment of gastroparesis considering the state of carbohydrate metabolism in patients with type 2 diabetes mellitus

2017 ◽  
Author(s):  
Iryna Kostitska
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
The State

The state of carbohydrate metabolism and the development of cerebrovascular diseases in patients with type 2 diabetes mellitus

Pharmateca ◽  
2019 ◽  
Vol 4_2019 ◽  
pp. 61-67
Author(s):  
K.V. Antonova () Antonova ◽  
M.M. Tanashyan () Tanashyan ◽  
M.Yu. Maksimova () Maksimova ◽  
N.V. Shakhparonova () Shakhparonova ◽  
T.I. Romantsova () Romantsova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Cerebrovascular Diseases ◽  
The State

Comparison of chosen clinical markers in patients with type 2 diabetes mellitus and latent carbohydrate metabolism disorders

2008 ◽  
Vol 63 (1) ◽  
pp. 221-224
Author(s):  
Magdalena Glazer ◽  
Piotr Przybylski ◽  
Grzegorz Glazer ◽  
Maria Kurowska
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Carbohydrate Metabolism ◽  
Clinical Markers

scholarly journals Lipid composition and Na+,K+-ATPase activity in erythrocyte membranes of patients with type 2 diabetes mellitusand dyslipoproteinemia

2010 ◽  
Vol 13 (1) ◽  
pp. 41-44 ◽  
Author(s):  
Elena Borisovna Kravets ◽  
Elena Alekseevna Stepovaya ◽  
Tatiana Yur'evna Koshchevets ◽  
Olesya Dmitrievna Medvedeva ◽  
Natalya Mikhailovna Yakovleva ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Atpase Activity ◽  
Carbohydrate Metabolism ◽  
Lipid Composition ◽  
Erythrocyte Membranes ◽  
Therapeutic Modalities

Aim. To study lipid composition and Na+,K+-Na+,K+-ATPase activity in erythrocyte membranes of patients with type 2 diabetes mellitus and dyslipoproteinemia. Materials and methods. The study included 40 patients (22 men and 18 women) aged 40-65 years with DM2. Results. The patients had abnormal lipid composition and impaired Na+,K+-Na+,K+-ATPase activity in erythrocyte membranes. The magnitude of thesechanges depended on the duration of pathology, severity of diabetic dyslipoproteinemia, and quality of compensation of carbohydrate metabolism. Conclusion. Aim. Investigation of lipid dysorganization in erythrocyte membranes in patients with type 2 diabetes mellitus yields data for the developmentof therapeutic modalities to correct dyslipoproteinemia.

scholarly journals Chronic heart failure in patients with type 2 diabetes mellitus: prevalence, prognosis

2015 ◽  
Vol 6 (1) ◽  
pp. 16-23
Author(s):  
S. V Kakorin ◽  
I. A Averkova ◽  
A. M Mkrtumyan
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Type 2 Diabetes Mellitus ◽  
Chronic Heart Failure ◽  
Carbohydrate Metabolism ◽  
The Status ◽  
Treatment Prognosis

The article presents a literature review of prevalence, prognosis and treatment of overt tactics of chronic heart failure (CHF) in patients with type 2 diabetes mellitus (T2DM). Diabetes and heart failure acquire the status of the epidemic of the XXI century and require health care costs for prevention and treatment of these diseases. Application of modern pharmacological preparations and instrumental treatment of cardiovascular disease (CVD) increases life expectancy and improves the quality of life of patients with CHF as with normal carbohydrate metabolism (UO), and with type 2 diabetes. However, the risk of cardiovascular mortality (CAS) in patients with type 2 diabetes, compared to having a normal carbohydrate metabolism remains unchanged. The rapidly growing population of patients with type 2 diabetes will soon change this in recent years to improve representation treatment prognosis of cardiovascular disease. Violation of myocardial remodeling in type 2 diabetes is caused by a combination of factors associated with diabetic cardiomyopathy. Reduction of the metabolic activity of cardiomyocytes insufficient glucose transport into cells, endothelial dysfunction, diabetic macro and microangiopathy myocardial fibrosis leading to disruption of filling the left ventricle (LV) and the development of chronic heart failure.Insulin resistance (IR) and compensatory hyperinsulinemia (GI) play a key role in the pathogenesis of type 2 diabetes. With effective treatment of chronic heart failure by cardiologists in patients with type 2 diabetes, affecting therapy with insulin resistance should be mandatory.

scholarly journals Iron metabolism parameters and inflammatory status in patients with diabetes mellitus and dyslipidemia

2020 ◽  
Vol 17 (3) ◽  
pp. 269-282
Author(s):  
Nadezhda N. Musina ◽  
Tatiana V. Saprina ◽  
Tatiana S. Prokhorenko ◽  
Anastasia P. Zima
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 1 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profile ◽  
Carbohydrate Metabolism ◽  
Iron Metabolism ◽  
Inflammatory Status

Background: Investigating the inflammatory status and iron metabolism in patients with impaired carbohydrate metabolism seems quite relevant, while only few studies are devoted to the relationship between metabolic parameters, including lipid profile, inflammatory status indicators and the state of ferrokinetics in diabetes mellitus types 1 and 2 in a comparative aspect.Aims: To establish the direction of changes in the inflammatory status and the state of ferrokinetics in patients with type 1 and type 2 diabetes mellitus depending on lipid metabolism disorders.Materials and methods: The study included 48 patients with type 1 diabetes, 81 patients with type 2 diabetes; 11 people with obesity without impaired carbohydrate metabolism made up the comparison group, 17 healthy volunteers - the control group. Low-grade inflammation was assessed by the levels of high-sensitive C-reactive protein (CRP), tumor necrosisfactor-а (TNF-а), ferritin, and erythrocyte sedimentation rate (ESR). The state of iron metabolism was evaluated by the main hematological parameters (hemoglobin, red blood cell count, hematocrit), serum iron concentrations, transferrin, ferritin and hepcidin concentrations. In all patients lipid metabolism parameters, glycated hemoglobin, and microalbuminuria were measured.Results: Patients with type 1 and type 2 diabetes mellitus had significantly higher inflammatory markers concentrations-TNF-а, ESR, and CRP - in relation to obese patients without impaired carbohydrate metabolism and those in the control group. The highest production of TNF-а was observed in patients with type 1 diabetes mellitus (15.28 [12.41-24.41] pg/ml), whereas CRP (7.00 [3.00-11.85] ng/ml) and ESR (18.00 [9.00-27.00] mm/h) were higher in patients with type 2 diabetes. In the structure of the examined individuals with diabetes mellitus (regardless of its type), dyslipidemia type IIb in comparison with less atherogenic type IIa dyslipidemia was characterized by a higher production of CRP (6.9 [3.00-12.35] and 3.00 [1.80-8.70] ng/ml, respectively), ESR (20.00 [10.00-30.00] and 15.00 [5.00-24.50] mm/h, respectively) and ferritin (114.80 [48.90-196.45] and 50.90 [19.58-114.10] ng/ml, respectively). Compared to iron deficiency anemia, anemia of chronic diseases in diabetes mellitus patients was more often accompanied by dyslipidemia llb (χ2=2.743; p=0.098) and was characterized by a higher content of atherogenic fractions of cholesterol.Conclusions: Patients with type 2 diabetes mellitus and a more atherogenic dyslipidemia profile (type IIb) have a phenotype of the local inflammatory mesenchymal reaction of the liver with an increase in acute-phase proteins predominantly of hepatic origin (CRP, ferritin), whereas individuals suffering from type 1 diabetes and less atherogenic lipid profile (type IIa) have a phenotype of an autoimmune, genetically determined inflammatory response. It has been established that anemia of chronic diseases developing in the background of diabetes mellitus is associated with a more atherogenic lipid profile, compared with iron deficiency anemia.

Sign in / Sign up

Export Citation Format

Share Document